Breakout Stocks of Week 12 @ FRA
NASDAQ was down last week (week 11) by -0.696% ending at 15,973.17 points after falling -111.94 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Volkswagen AG FRA:VOW3. This stock has had a buy signal since Mar 15, 2024 when the price was 113.78€ , but have so far fallen 0% to 113.78€. Some other companies are on our watchlist to, among these are which all got a breakout pattern emerging.
| Date | Company | Price | Week 12 |
|---|---|---|---|
| Volkswagen Ag | 113.78€ | 118.08€ | 3.78% |
| Deutsche Börse Aktiengesellschaft | 185.25€ | 185.60€ | 0.189% |
The Volkswagen AG stock price gained 0.744% on the last trading day (Friday, 15th Mar 2024), rising from 112.94€ to 113.78€. During the last trading day the stock fluctuated 1.48% from a day low at 113.30€ to a day high of 114.98€. The price has fallen in 6 of the last 10 days and is down by -4.51% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 887 thousand more shares were traded than the day before. In total, 4 million shares were bought and sold for approximately 401.82€ million.
Volkswagen AG holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Volkswagen AG:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
The Deutsche Börse Aktiengesellschaft stock price fell by -0.750% on the last day (Friday, 15th Mar 2024) from 186.65€ to 185.25€. During the last trading day the stock fluctuated 1.76% from a day low at 184.95€ to a day high of 188.20€. The price has been going up and down for this period, and there has been a -3.94% loss for the last 2 weeks. Volume has increased on the last day by 722 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately 277.95€ million.
The Deutsche Börse Aktiengesellschaft stock holds several negative signals and despite the positive trend, we believe Deutsche Börse Aktiengesellschaft will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About Deutsche Börse Aktiengesellschaft:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
